Glenmark introduces the Sacu VTM to treat chronic heart failure

Glenmark Pharmaceuticals Ltd. has introduced'sacubitril + valsartan' tablets in India, which are indicated for patients with chronic heart failure (NYHA class II-IV) and a low ejection fraction (HFrEF). It is marketed as 'Sacu VTM' and must be taken twice daily with a doctor's prescription. The sacubitril-valsartan combination is an Angiotensin Receptor Neprilysin Inhibitor (ARNI). In the treatment of heart failure, these molecules have two therapeutic targets: the natriuretic peptide (NP) system for sacubitril and the Renin-Angiotensin System (RAS) for valsartan.

The use of sacubitril plus valsartan has been recommended by the most recent heart failure treatment guidelines in Europe and the United States. Glenmark Pharmaceuticals Ltd. has launched'sacubitril + valsartan' tablets in India for patients with chronic heart failure (NYHA class II-IV) and a low ejection fraction (HFrEF). It's marketed as 'Sacu VTM,' and it has to be taken twice a day with a doctor's prescription. The combination of sacubitril and valsartan is an Angiotensin Receptor Neprilysin Inhibitor (ARNI). These molecules have two therapeutic targets in the treatment of heart failure: the natriuretic peptide (NP) system for sacubitril and the Renin-Angiotensin System (RAS) for valsartan. The most recent heart failure treatment guidelines in Europe and the United States both recommend the use of sacubitril plus valsartan.